T lymphocyte membrane-decorated epigenetic nanoinducer of interferons for cancer immunotherapy

Zhai, Yi­hui; Wang, Jinming; Lang, Tianqun; Kong, Ying; Rong, Rong; Cai, Ying; Wei, Ran; Xiong, Fengqin; Zheng, Chao; Wang, Yanke; Yu, Yang; Zhu, Helen He; Zhang, Pengcheng; Li, Yaping

doi:10.1038/s41565-021-00972-7

Cited by 95 publications

(66 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…124 Thus, Zhai et al prepared epigenetic regulation nanovesicles (OPEN) using a GSH-responsive cross-linker (NHS-SS-NHS) to cross-link albumin and an IFN inducer (ORY-1001), and then enclosed the nanogel with engineered T cell membrane vesicles highly expressing PD1, and a modified penetrating peptide M70 was placed on the surface to enhance the penetration and release of ORY-1001. 125 After intravenous injection into tumour-bearing mice, OPEN actively targeted the tumour cells due to the recognition of PD1/PDL1. At the tumour site, the disulfide bond was broken under the activation of over-expressed GSH in the tumour and the release of ORY-1001 up-regulated the expression of IFN, which promoted the activation of APCs and antigen presentation.…”

Section: Nanogels For Immunomodulatory Therapeuticsmentioning

confidence: 99%

Bioengineered nanogels for cancer immunotherapy

Liu

et al. 2022

Chem. Soc. Rev.

View full text Add to dashboard Cite

show abstract

Section: Nanogels For Immunomodulatory Therapeuticsmentioning

confidence: 99%

Bioengineered nanogels for cancer immunotherapy

Liu

et al. 2022

Chem. Soc. Rev.

View full text Add to dashboard Cite

show abstract

“…In addition to surface modification, the surface of nanoparticles can also be coated with cell membranes for specific identification. As a typical example, Li et al presented a nanoinducer engineered with programmed cell death protein 1 (PDL1) and coated with T lymphocyte membrane for cancer immunotherapy [141]. It was demonstrated that the nanoinducer can target the PDL1 ligands and induce the generation and internalization of interferons.…”

Section: Active Targeting Systemsmentioning

confidence: 99%

Developing sensor materials for screening intestinal diseases

Zhao¹,

Zhang²,

Chen³

et al. 2022

Mater. Futures

View full text Add to dashboard Cite

Intestinal diseases have always been the focus of clinicians and scientific researchers, which have high mortality and morbidity rates, and bring huge encumbrance on the public medical system and economy worldwide. In the progression of many intestinal diseases, early diagnosis and intervention are valuable. Fortunately, the emergence of sensor materials can effectively assist clinical early diagnosis and health monitoring. By accurately locating the lesion and sensitively analyzing the level of disease markers, these sensor materials can help to precisely diagnose the stage and state of lesions, thereby avoiding delaying the treatment. In this review, we provide a comprehensive and in-depth knowledge into diagnosing and monitoring intestinal diseases with the assistance of sensor materials, particularly emphasizing the design and application of them in bioimaging and biodetection. This review is dedicated to conveying the practical applications of sensor materials in the intestine, a critical analysis of their mechanisms and applications, and discussion of their future roles in medicine. We believe that this review would promote the multidisciplinary communication between material science, medicine, and the relevant engineering fields, thus improving the clinical translation of sensor materials

show abstract

“…Recently, a T‐lymphocyte membrane‐modified nanocarrier was created to deliver an IFN inducer ORY 1001, altering epigenetic information to increase local concentrations of IFN. [ 85 ] The nanocarrier was enveloped by programmed cell death 1(PD‐1), overexpressing the T lymphocyte membrane that helps block the immune checkpoint ligands. After intravenous injection, the ENs released ORY 1001 to upregulate intratumoral IFN‐α/β levels and increase downstream MHC‐I and PD‐L1.…”

Section: Application Of Engineered Nanoplatforms To Break the Immunos...mentioning

confidence: 99%

Breaking Immunosuppressive Barriers by Engineered Nanoplatforms for Turning Cold Tumor to Hot

Dong

Huang

Zhou

et al. 2022

Advanced Therapeutics

View full text Add to dashboard Cite

Cancer immunotherapy, mainly depending on the immune system, holds enormous potential in treating various cancers and received promising results. However, for most patients, their efficacy is greatly limited by the immunosuppressive barrier in the "cold" tumor microenvironment, resulting in a low response rate in the clinic. Thus, in recent decades, breaking the immunosuppressive barriers by engineered nanoplatforms (ENs) has proved to be a prospective strategy to solve the above issues for enhancing cancer immunotherapy. In this review, the authors summarize the characterizations of diverse immunosuppressive barriers and how ENs break them, focusing on the ENs design, potential modulation targets, and therapeutic strategies. It mainly includes: 1) converting poor immunogenicity by nano-adjuvant, 2) alleviating tumor fibrosis by nanoscavenger, and 3) reducing immunosuppressive factors by nanoregulator. Moreover, perspectives toward future directions and challenges are presented to understand further and accelerate the clinical translation of these ENs.

show abstract

T lymphocyte membrane-decorated epigenetic nanoinducer of interferons for cancer immunotherapy

Cited by 95 publications

References 47 publications

Bioengineered nanogels for cancer immunotherapy

Bioengineered nanogels for cancer immunotherapy

Developing sensor materials for screening intestinal diseases

Breaking Immunosuppressive Barriers by Engineered Nanoplatforms for Turning Cold Tumor to Hot

Contact Info

Product

Resources

About